Drug Trial Radar · NCT06639984
Psyllium in Pediatric IBS
Last checked: Nov 20, 2026Latest source record: May 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Feb 20, 2025
Primary completion
Sep 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- Dr Bruno Chumpitazi, M.D.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if a fiber (psyllium) can change the way bacteria use fructans (a type of sugar) and whether psyllium can help decrease childhood irritable bowel syndrome (IBS) symptoms when eating fructans. The main questions it aims to answer are: Aim 1: The effect of psyllium at two doses given with a fructan meal on microbial fructan fermentation (intracolonic pH; H2 gas production; gut microbiome composition; fecal short-chain fatty acids, lactate, glycomics). Aim 2: Determine the impact of psyllium given with a fructan meal on fructan-induced GI symptoms. Participants will first be asked to eat a specific diet over two three-day periods to determine if fructans worsen their IBS symptoms. Those with worsening symptoms with fructans will be asked to participate in the second part of the study. This includes two weeks of baseline (no change in diet) and two weeks of eating a specific diet with fructans with either psyllium or glucose. Participants will be asked to complete pain and stool diaries, submit stool specimens, swallow a pill to capture gut acid levels, and give breath samples.
Conditions
- Irritable Bowel Syndrome
Interventions
Psyllium (0.7 g/year of age per day)Drug
Psyllium (0.7 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
Psyllium (0.5 g/year of age per day)Drug
Psyllium (0.5 g/year of age per day) (Konsyl Pharmaceuticals, Easton, MD)
PlaceboDrug
Placebo (0.7 g/year of age glucose) (Staleydex 333; Tate \& Lyle, Staley, London, UK)
fructansOther
Daily dose 0.5 g/kg up to 19 grams, Orafti Synergy1
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in microbiome composition measured via taxonomic profiling using 16S ribosomal RNA gene amplicon sequencingTime frame: Baseline, 2 weeks
- Change in fecal lactateTime frame: Baseline, 2 weeks
- Change in fecal short-chain fatty acidsTime frame: Baseline, 2 weeks
- Change in hydrogen gas productionTime frame: Baseline, 2 weeks
- Change in fecal fructansTime frame: Baseline, 2 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Duke University
Durham, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.